Trials / Completed
CompletedNCT03083821
A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting
A Clinical Study to Evaluate the Steady State Pharmacokinetics of Baraclude in Participants With Hepatitis B Virus Infection
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A Pharmacokinetics study of Baraclude in a real world clinical setting in Japan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Baraclude | Specified dose on specified day |
Timeline
- Start date
- 2017-05-16
- Primary completion
- 2017-12-19
- Completion
- 2017-12-19
- First posted
- 2017-03-20
- Last updated
- 2023-11-18
- Results posted
- 2023-11-18
Locations
1 site across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03083821. Inclusion in this directory is not an endorsement.